Cell therapy and brain function in AIHA
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial looks at how cell therapy may affect your brain function and mood if you have autoimmune hemolytic anemia. It aims to help doctors understand the psychological changes that can happen during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with autoimmune hemolytic anemia (AIHA).
- You are planning to receive cell therapy (like CAR T-cell therapy) for your AIHA.
- You are between 18 and 65 years old.
- You are willing to follow the study rules and give your written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This trial looks at how CAR-T treatment affects the brain and thinking skills. It aims to better understand and help with side effects like confusion or memory problems.
This trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can help control the disease when other options have failed.
This study uses brain scans and blood markers to understand how CAR T-cell therapy affects the brain. It may help researchers predict or manage potential side effects.
This trial tests a new cell therapy (YTS109) for people with autoimmune hemolytic anemia (AIHA) that has not responded to at least three prior treatments. The goal is to see if this therapy can help control the disease.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.